AbbVie Data Show Skyrizi Tops IL-17 Competitors In Skin Clearance
Skyrizi showed better skin-clearance results than Cosentyx or Taltz in a 52-week study of patients who had suboptimal results on the latter two drugs.
You may also be interested in...
Humira’s US revenue declines by 26% as biosimilar adalimumab makes its debut. Follow-ons Skyrizi and Rinvoq post strong growth, but fall short of Street consensus estimates.
In this week's podcast version of Five Must-Know Things: Merck remains confident in TIGIT; Otezla and Sotyktu battle for share in psoriasis; GSK chief warns about worsening UK pharma sector; China plans to ban gene editing technology exports; and an interview with Boehringer Ingelheim’s head of human pharma regions.
With adalimumab biosimilars now on market in the US, AbbVie said it expects sales erosion this year toward the lower end of its previous guidance, with pricing comprising the larger portion of the hit.